PFM
GILD icon

Privium Fund Management’s Gilead Sciences GILD Stock Holding History

Privium Fund Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,418
Closed -$211K – 231
2022
Q2 		$211K Sell
3,418
-2,708
-44% -$168K 0.07% 97
2022
Q1 		$364K Buy
6,126
+3,267
+114% +$209K 0.08% 105
2021
Q4 		$210K Buy
+2,859
New +$197K 0.04% 107

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Privium Fund Management's GILD Position: Q3 2022 in Review

Privium Fund Management sold out of Gilead Sciences (GILD) in Q3 2022, closing a stake of 3,418 shares — an estimated $211K sold.

Privium Fund Management first reported a position in GILD in Q4 2021 and held it in 3 quarters. The position peaked at $364K in Q1 2022. 1,604 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

  • Privium Fund Management reported no remaining Gilead Sciences position as of Q3 2022 after selling out during the quarter.
  • Privium Fund Management sold 3,418 Gilead Sciences shares in Q3 2022, an estimated $211K.
  • Privium Fund Management first reported a position in Gilead Sciences in Q4 2021 and held it in 3 quarters.
  • Privium Fund Management's Gilead Sciences position peaked at $364K in Q1 2022.
  • 1,604 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on Privium Fund Management's 13F filing for Q3 2022, filed 3 Nov 2022.